High Point's biopharmaceutical company vTv Therapeutics is back in good standing with Nasdaq after months of being in danger of being delisted. At its lowest point in the past year, the company's stock had traded for $0.35 per share. Find out just how big a jump the stock price took and if this means the company, which is developing an oral treatment for Type 1 diabetes, is truly in good financial standing.
